首页 | 本学科首页   官方微博 | 高级检索  
     


Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial
Authors:Subodh Verma MD  Abhinav Sharma MD  Bernard Zinman MD  Anne Pernille Ofstad MD  David Fitchett MD  Martina Brueckmann MD  Christoph Wanner MD  Isabella Zwiener PhD  Jyothis T. George MBBS  Silvio E. Inzucchi MD  Javed Butler MD  C. David Mazer MD
Affiliation:1. Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada;2. McGill University Health Centre, McGill University, Montreal, Quebec, Canada;3. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada;4. Boehringer Ingelheim Norway KS, Asker, Norway;5. Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada;6. Boehringer Ingelheim International GmbH, Ingelheim, Germany

Faculty of Medicine Mannheim of the University of Heidelberg, Mannheim, Germany;7. Würzburg University Clinic, Würzburg, Germany;8. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany;9. Boehringer Ingelheim International GmbH, Ingelheim, Germany;10. Yale University School of Medicine, New Haven, Connecticut;11. Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi;12. Department of Anesthesia, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

Abstract:
Keywords:cardiovascular disease   clinical trial   heart failure   randomized trial   sodium-glucose co-transporter-2 inhibitor   type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号